论文部分内容阅读
目的:观察FOLFOX4和TP方案一线治疗晚期胃癌的疗效和不良反应。方法:收集41例接受FOL-FOX4方案或TP方案一线治疗的晚期胃癌患者的临床资料,其中FOLFOX4组21例,奥沙利铂(L-OHP)85mg/m~2,静滴,第1天;CF 200mg/m~2,静滴,第1、2天;5-FU 400mg/m~2,静推,第1、2天;5-FU 600mg/m~2持续静注22h,第1、2天,14d为一周期,共12周期。TP组20例,紫杉醇(TAX)剂量为135mg/m~2,静滴,第1天;DDP 80mg/m~2静滴,第1天,21d为一周期,共6周期。结果:FOLFOX4组和TP组的客观缓解率分别47.6%和45%(P=0.958);中位疾病进展时间为6.70个月和6.20个月(P=0.943);中位生存时间分别为9.50个月和7.80个月(P=0.587)。两组方案主要不良反应为血液学毒性及恶心呕吐,FOLFOX4组和TP组Ⅲ度～Ⅳ度白细胞下降发生率为14.3%和30.0%(P=0.321),Ⅲ度～Ⅳ度中性粒细下降发生率为19.0%和30.0%(P=0.731)。结论:FOLFOX4方案和TP方案一线治疗晚期胃癌疗效相近,毒性均可耐受。
Objective: To observe the efficacy and side effects of FOLFOX4 and TP regimen in the treatment of advanced gastric cancer. Methods: The clinical data of 41 patients with advanced gastric cancer treated with first-line FOL-FOX4 or TP regimen were collected. Among them, 21 patients in FOLFOX4 group, 85 mg / m 2 in oxaliplatin (L-OHP) ; CF-200mg / m ~ 2, intravenous infusion, days 1 and 2; 5-FU 400mg / m ~ , 2 days, 14d for a cycle, a total of 12 cycles. TP group 20 patients, paclitaxel (TAX) dose of 135mg / m ~ 2, intravenous infusion, the first day; DDP 80mg / m ~ 2 intravenous infusion, the first day, 21d for a cycle, a total of 6 cycles. Results: The objective response rates of FOLFOX4 group and TP group were 47.6% and 45% respectively (P = 0.958). The median progression time was 6.70 months and 6.20 months (P = 0.943), and the median survival time was 9.50 Month and 7.80 months (P = 0.587). The main adverse reactions of the two groups were hematological toxicity and nausea and vomiting. The incidences of grade Ⅲ ~ Ⅳ leukopenia in FOLFOX4 group and TP group were 14.3% and 30.0%, respectively (P = 0.321), and Ⅲ ~ Ⅳ neutropenia The incidence was 19.0% and 30.0% (P = 0.731). Conclusion: The first-line treatment of advanced gastric cancer with FOLFOX4 regimen and TP regimen has similar efficacy and tolerability.